BUZZ-Vor Bio jumps as J.P.Morgan initiates with 'overweight' rating

Reuters12-09 19:49
BUZZ-Vor Bio jumps as J.P.Morgan initiates with 'overweight' rating

** Shares of Vor Biopharma VOR.O rise 67% to $13.97 premarket

** J.P.Morgan starts coverage with "overweight" rating and PT of $43, which represents 414% upside to the stock's last close

** Brokerage says VOR's autoimmune disease drug, telitacicept, licensed from China's RemeGen 688331.SS, is considered "highly de-risked across a range of indications" due to strong late-stage data from China

** Telitacicept is being developed to treat Myasthenia Gravis, a muscle weakening disorder, and primary Sjögren's Disease, condition that causes dry eyes and mouth

** J.P.Morgan "conservatively assume(s) blockbuster peak sales for telitacicept in the U.S. alone" in both indication

** Current share price seen as undervalued, given "probability-adjusted value of telitacicept in MG and pSD alone" - J.P.Morgan

** Stock down 62% YTD

(Reporting by Kamal Choudhury in Bengaluru)

((Kamal.Choudhury@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment